- Home
- RNXT vs INMB Comparison
RNXT vs INMB Comparison
Compare RNXT & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNXT | INMB |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.4M | 64.7M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RNXT | INMB |
|---|---|---|
| Price | $1.52 | $1.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $7.13 | $7.00 |
| AVG Volume (30 Days) | ★ 1.1M | 299.4K |
| Earning Date | 11-12-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,123,000.00 | $50,000.00 |
| Revenue This Year | $244.84 | N/A |
| Revenue Next Year | $195.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2511.63 | 257.14 |
| 52 Week Low | $0.70 | $1.09 |
| 52 Week High | $2.59 | $2.60 |
Technical Indicators
Market Signals| Indicator | RNXT | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 41.45 |
| Support Level | $1.55 | $1.97 |
| Resistance Level | $1.80 | $2.17 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 22.86 | 6.25 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.